EX-99.7 6 d524048dex997.htm EX-99.7 EX-99.7

Exhibit 99.7

UNAUDITED PRO FORMA COMBINED FINANCIAL

INFORMATION

Introductory Note

On May 31, 2023, Cibus, Inc. (the “Company”, and prior to the closing of the Mergers, “Calyxt, Inc.” or “Calyxt”) completed its business combination in accordance with the terms of the Agreement and Plan of Merger, dated as of January 13, 2023, as amended by the First Amendment thereto dated as of April 14, 2023 (as amended, the “Merger Agreement”), by and among Calyxt; Calypso Merger Subsidiary, LLC, a wholly-owned subsidiary of Calyxt (“Merger Subsidiary”); Cibus Global, LLC, (“Cibus Global”); and certain blocker entities (the “Blockers”), pursuant to which, among other matters, (a) each of the Blockers merged with and into Calyxt, (c) following the Blocker Mergers, Merger Subsidiary merged with and into Cibus Global (the “Cibus Merger” and, collectively with the Blocker Mergers, the “Mergers”), with Cibus Global as the surviving company and Merger Subsidiary ceasing to exist. In connection with the Mergers, Calyxt contributed all of its assets and liabilities to Cibus Global, as a contribution to the capital of Cibus Global, in exchange for newly issued membership units of Cibus Global, pursuant to a contribution agreement between Calyxt and Cibus Global. Pursuant to the Merger Agreement, upon the effective time, the Company changed its name from Calyxt, Inc. to Cibus, Inc.

On May 31, 2023 and prior to the Mergers, Calyxt effected a 1-for-5 reverse stock split of its common stock (the “Second Reverse Stock Split”). In addition, on April 24, 2023, Calyxt effected a 1-for-10 reverse stock split of its common stock (the “First Reverse Stock Split” and, together with the Second Reverse Stock Split, the “Reverse Stock Splits”).

At the closing of the Mergers, each share of Calyxt common stock existing and outstanding immediately prior to the Mergers remained outstanding as a share of Class A Common Stock and the Company issued an aggregate of 16,527,484 shares of Class A Common Stock (and together with the Class B Common Stock, the “Shares”), including 1,019,282 shares of restricted Class A Common Stock, and 4,642,635 shares of Class B Common Stock to Cibus unitholders, based on an exchange ratio set forth in the Merger Agreement.

Unaudited Pro Forma Combined Financial Information

The following unaudited pro forma combined financial information presents the combination of the historical financial statements of Calyxt, Inc. and the historical financial statements of Cibus Global, after giving effect to the Mergers.

The following unaudited pro forma combined financial information gives effect to the transaction accounting adjustments, which consist of the Mergers, and the Reverse Stock Splits.

In the unaudited pro forma combined financial information, the Mergers have been accounted for as a business combination, using the acquisition method of accounting under U.S. GAAP where Calyxt, Inc. is considered the acquirer of Cibus Global for accounting purposes. For accounting purposes, the acquirer is the entity that has obtained control of another entity and, thus, consummated a business combination. The determination of whether control has been obtained begins with the evaluation of whether control should be evaluated under the variable interest or voting interest model pursuant to ASC Topic 810, Consolidation (“ASC 810”). If the acquiree is a variable interest entity, the primary beneficiary would be the accounting acquirer. Cibus Global meets the definition of a variable interest entity, and Calyxt, Inc., which is the managing member of Cibus Global, has been determined to be the primary beneficiary.

Under the acquisition method of accounting, the assets and liabilities associated with Cibus Global are recorded at their estimated fair value as of the acquisition date. The excess of the purchase price over the estimated fair values of the net assets acquired, if applicable, are recognized as goodwill. For purposes of the unaudited pro forma combined balance sheet, the purchase consideration has been allocated to the assets acquired and liabilities assumed of Cibus Global based upon management’s preliminary estimate of their fair values and are subject to change. Accordingly, the value of Cibus Global assets and liabilities recognized should be treated as preliminary values.


The unaudited pro forma combined balance sheet data as of March 31, 2023 assumes that the Mergers took place on March 31, 2023 and combines the Calyxt, Inc., and Cibus Global historical balance sheets as of March 31, 2023. The unaudited pro forma combined statement of operations data for three months ended March 31, 2023 and for the year ended December 31, 2022 gives effect to the Mergers as if they took place on January 1, 2022 and combines the historical results of Calyxt, Inc. and Cibus Global for the three months ended March 31, 2023 and the year ended December 31, 2022, respectively.

The historical financial statements of Calyxt, Inc. and Cibus Global have been adjusted to give pro forma effect to reflect the accounting for the transactions in accordance with U.S. GAAP. The adjustments presented on the unaudited pro forma combined financial statements have been identified and presented to provide relevant information necessary for an accurate understanding of the Company, including all of its subsidiaries (including Cibus Global) (collectively on a consolidated basis, the “Combined Company”) upon consummation of the Mergers.

The unaudited pro forma combined financial information is based on assumptions and adjustments that are described in the accompanying notes and is for illustrative purposes only. The unaudited pro forma combined financial information should not be relied upon as being indicative of the historical results that would have been achieved had the companies always been combined or the future results that the Combined Company will experience. The actual amounts recorded as of the completion of the Mergers may differ materially from the information presented in the unaudited pro forma combined financial information as a result of finalization of the fair value of Cibus Global’s assets and liabilities assumed that will occur after the completion of the Mergers.

The unaudited pro forma combined financial information, including the notes thereto, should be read in conjunction with the audited consolidated financial statements of Cibus Global as of and for the year ended December 31, 2022, included elsewhere in the Current Report on Form 8-K/A of Cibus, Inc. filed with the SEC on June 29, 2023 (the “Form 8-K/A”), Cibus Global’s interim financial statements as of and for the three-month period ended March 31, 2023, which are included in the Form 8-K/A, and the audited financial statements of Calyxt, Inc. as of and for the year ended December 31, 2022, which are included in Calyxt Inc.’s annual report on Form 10-K/A, filed with the U.S. Securities and Exchange Commission (the “SEC”) on March 3, 2023, and the interim financial statements of Calyxt, Inc. as of and for the three-month period ended March 31, 2023, which are included in Calyxt, Inc.’s quarterly report on Form 10-Q, filed with the SEC on May 1, 2023.


Unaudited Pro Forma Combined Balance Sheet    

As of March 31, 2023

(in thousands)

 

                 Transaction           Pro Forma  
                 Accounting           Combined  
     Calyxt, Inc.     Cibus Global     Adjustments     Note 5     Total  

Assets

          

Current assets:

          

Cash and cash equivalents

   $ 2,054     $ 13,997     $ —         $ 16,051  

Accounts receivable

     —         1,413       —           1,413  

Due from related parties, net

     —         196       —           196  

Employee retention credit receivable

       2,062           2,062  

Notes receivable

     —         1,000       (1,000     (i)       —    

Prepaid expenses and other current assets

     529       1,182       —           1,711  
  

 

 

   

 

 

   

 

 

     

 

 

 

Total current assets

     2,583       19,850       (1,000       21,433  

Land, buildings, and equipment

     4,104       6,679       3,624       (h)       14,407  

Operating lease right-of-use-assets

     13,493       10,150       —           23,643  

Other non-current assets

     105       471       —           576  

Intangible assets, net

     —         —         43,966       (h)       43,966  

Goodwill

     —         —         659,376       (h)       659,376  
  

 

 

   

 

 

   

 

 

     

 

 

 

Total assets

   $ 20,285     $ 37,150     $ 705,966       $ 763,401  
  

 

 

   

 

 

   

 

 

     

 

 

 

Liabilities, redeemable noncontrolling interest and shareholders’ equity (deficit)

          

Current liabilities:

          

Accounts payable

   $ 327     $ 4,255     $ —         $ 4,582  

Accrued expenses

     1,052       2,925       5,434       (a)(f)       9,411  

Accrued compensation

     180       3,348       —           3,528  

Due to related party

     63       79       —           142  

Deferred revenue

     —         1,292       —           1,292  

Notes payable, current portion

     —         614       —           614  

Current portion of financing lease obligations

     —         152       —           152  

Common stock warrants

     1,110       —         —           1,110  

Short-term debt

     1,000       —         (1,000     (i)       —    

Other current liabilities

     483       5,726       —           6,209  
  

 

 

   

 

 

   

 

 

     

 

 

 

Total current liabilities

     4,215       18,391       4,434         27,040  

Notes payable, net of current portion

     —         727       —           727  

Operating lease obligations

     13,342       6,735       —           20,077  

Financing lease obligations

     —         49       —           49  

Royalty liability - related parties

     —         52,666       29,278       (h)       81,944  

Other non-current liabilities

     61       1,519       —           1,580  
  

 

 

   

 

 

   

 

 

     

 

 

 

Total liabilities

     17,618       80,087       33,712         131,417  
  

 

 

   

 

 

   

 

 

     

 

 

 

Redeemable noncontrolling interest

     —         —         138,235       (j)       138,235  

Shareholders’ equity:

          

Series A convertible preferred units

     —         64,097       (64,097     (j)       —    

Series B convertible preferred units

     —         54,710       (54,710     (j)       —    

Series C convertible preferred units

     —         67,012       (67,012     (j)       —    

Series D convertible preferred units

     —         54,195       (54,195     (j)       —    

Series E convertible preferred units

     —         34,381       (34,381     (j)       —    

Series F convertible preferred units

     —         58,562       (58,562     (j)       —    

Voting common units

     —         —         —           —    

Nonvoting common units

     —         1,284       (1,284     (j)       —    

Common stock

     1       —         1       (b)(j)       2  

Common stock in treasury, at cost

     (1,043     —         —           (1,043

Unit subscription receivable

     —         (4,080     4,080       (c)(j)       —    

Additional paid-in capital

     221,254       57,311       443,608       (c)(j)       722,173  

Accumulated other comprehensive income (loss)

     —         —         —         (c)(j)       —    

Accumulated deficit

     (217,545     (430,409     420,571       (c)(j)       (227,383
  

 

 

   

 

 

   

 

 

     

 

 

 

Total shareholders’ equity (deficit)

     2,667       (42,937     534,019         493,749  
  

 

 

   

 

 

   

 

 

     

 

 

 

Total liabilities, redeemable noncontrolling interest and shareholders’ equity (deficit)

   $ 20,285     $ 37,150     $ 705,966       $ 763,401  
  

 

 

   

 

 

   

 

 

     

 

 

 


Unaudited Pro Forma Combined Statement Of Operations    

For the Three Months Ended March 31, 2023    

(in thousand, except share and per share amounts)    

 

                 Transaction         Pro Forma  
                 Accounting         Combined  
     Calyxt, Inc.     Cibus Global     Adjustments     Note 5   Total  

Revenue

          

Collaboration and research - related party

   $ —       $ 193     $ —         $ 193  

Revenue

     42       —         —           42  
  

 

 

   

 

 

   

 

 

     

 

 

 

Total revenue

     42       193       —           235  
  

 

 

   

 

 

   

 

 

     

 

 

 

Operating expenses

          

Research and development

     2,209       9,822       —           12,031  

Selling, general and administrative

     2,296       5,208       (905   (a)(h)     6,599  
  

 

 

   

 

 

   

 

 

     

 

 

 

Total operating expenses

     4,505       15,030       (905       18,630  
  

 

 

   

 

 

   

 

 

     

 

 

 

Loss from operations

     (4,463     (14,837     905         (18,395

Interest income

     —         (2     —           (2

Interest expense

     21       66       —           87  

Interest expense, royalty liability - related parties

     —         3,341       —           3,341  

Other (income) expense, net

     910       29       —           939  
  

 

 

   

 

 

   

 

 

     

 

 

 

Total other (income) expense, net

     931       3,434       —           4,365  
  

 

 

   

 

 

   

 

 

     

 

 

 

Net loss

   $ (5,394   $ (18,271   $ 905       $ (22,760
  

 

 

   

 

 

   

 

 

     

 

 

 

Net loss attributable to redeemable noncontrolling interest

     —         —         (4,978   (g)     (4,978
  

 

 

   

 

 

   

 

 

     

 

 

 

Net loss attributable to combined company

   $ (5,394   $ (18,271   $ 5,883       $ (17,782
  

 

 

   

 

 

   

 

 

     

 

 

 

Net loss per share attributable to common stockholders, basic and diluted

   $ (5.46         $ (1.22
  

 

 

     

 

 

     

 

 

 

Weighted average common shares outstanding, basic and diluted

     988,139         10,954,470     (d)     14,526,123  
  

 

 

     

 

 

     

 

 

 


Unaudited Pro Forma Combined Statement of Operations    

For the Year Ended December 31, 2022    

(in thousands, except share and per share amounts)    

 

                 Transaction           Pro Forma  
           Cibus     Accounting           Combined  
     Calyxt, Inc.     Global     Adjustments     Note 5     Total  

Revenue

          

Collaboration and research

   $ —       $ 202     $ —         $ 202  

Collaboration and research - related party

     —         908       —           908  

Revenue

     157       —         —           157  
  

 

 

   

 

 

   

 

 

     

 

 

 

Total revenue

     157       1,110       —           1,267  
  

 

 

   

 

 

   

 

 

     

 

 

 

Operating expenses

          

Research and development

     11,553       33,461       —           45,014  

Selling, general and administrative

     10,974       16,779       12,178       (a)(e)(f)(h)       39,931  
  

 

 

   

 

 

   

 

 

     

 

 

 

Total operating expenses

     22,527       50,240       12,178         84,945  
  

 

 

   

 

 

   

 

 

     

 

 

 

Loss from operations

     (22,370     (49,130     (12,178       (83,678

Interest income

     —         (7     —           (7

Interest expense

     87       291       —           378  

Interest expense, royalty liability - related parties

     —         6,073       —           6,073  

Other (income) expense, net

     (5,566     66       —           (5,500
  

 

 

   

 

 

   

 

 

     

 

 

 

Total other (income) expense, net

     (5,479     6,423       —           944  
  

 

 

   

 

 

   

 

 

     

 

 

 

Net loss

   $ (16,891   $ (55,553   $ (12,178     $ (84,622
  

 

 

   

 

 

   

 

 

     

 

 

 

Net loss attributable to redeemable non controlling interest

     —         —         (18,510     (g)       (18,510
  

 

 

   

 

 

   

 

 

     

 

 

 

Net loss attributable to combined company

   $ (16,891   $ (55,553   $ 6,332       $ (66,112
  

 

 

   

 

 

   

 

 

     

 

 

 

Net loss per share attributable to common stockholders, basic and diluted

   $ (18.36         $ (4.64
  

 

 

     

 

 

     

 

 

 

Weighted average common shares outstanding, basic and diluted

     919,951         10,885,266       (d)       14,254,388  
  

 

 

     

 

 

     

 

 

 


NOTES TO THE UNAUDITED PRO FORMA COMBINED FINANCIAL INFORMATION

1. Basis of Presentation

The unaudited pro forma combined financial information was prepared in accordance with U.S. GAAP and pursuant to the rules and regulations of Article 11 of Regulation S-X. The unaudited pro forma combined balance sheet as of March 31, 2023 was prepared using the historical consolidated balance sheets of Calyxt, Inc. and Cibus Global as of March 31, 2023. The unaudited pro forma combined statement of operations for the three months ended March 31, 2023 and the year ended December 31, 2022 was prepared using the historical consolidated statements of operations of Calyxt, Inc. and Cibus Global for the three months ended March 31, 2023 and the year ended December 31, 2022, respectively, and gives effect to the Mergers as if they occurred on January 1, 2022.

The unaudited pro forma combined financial information has been prepared using the acquisition method of accounting under U.S. GAAP. Calyxt, Inc. is deemed the accounting acquirer in the Mergers for accounting purposes and Cibus Global is treated as the accounting acquiree. For accounting purposes, the acquirer is the entity that has obtained control of another entity and, thus, consummated a business combination. The determination of whether control has been obtained begins with the evaluation of whether control should be evaluated under the variable interest or voting interest model pursuant to ASC 810. If the acquiree is a variable interest entity, the primary beneficiary would be the accounting acquirer. Cibus Global meets the definition of a variable interest entity and Calyxt, Inc., which is the managing member of Cibus Global, has been determined to be the primary beneficiary.

The application of acquisition accounting to Cibus Global is dependent upon other factors such as the share price of Calyxt, Inc. as well as certain valuations that have yet to progress to a stage where there is sufficient information for a definitive measurement. Following the closing of the Mergers, the Combined Company is in the process of completing the valuations and will finalize the purchase price allocation as soon as practicable within the measurement period, but in no event later than one year following the closing of the Mergers. The assets and liabilities of Cibus Global and other pro forma adjustments have been measured based on various preliminary estimates using assumptions the Company believes are reasonable, based on information that is currently available. Accordingly, the pro forma adjustments are preliminary. Differences between these preliminary estimates and the final acquisition accounting could be significant, and these differences could have a material impact on the accompanying unaudited pro forma combined financial information and the Combined Company’s future results of operations and financial position.

The unaudited pro forma combined financial information does not include the impact of any cost or other operating synergies that may result from the Mergers or any related restructuring costs that may be contemplated.

To the extent there are significant changes to the business of the Combined Company following completion of the Mergers, the assumptions and estimates set forth in the unaudited pro forma combined financial information could change significantly. Accordingly, the pro forma adjustments are subject to change as additional information becomes available and as additional analyses are conducted following the completion of the Mergers. There can be no assurances that these additional analyses will not result in material changes, including the estimates of fair value of Cibus Global’s assets and liabilities.

2. Purchase Price

The accompanying unaudited pro forma combined financial information reflects a purchase price of approximately $634.8 million, which consists of the following:

 

Number of Shares received by Cibus Global equityholders as merger
consideration (1)

     20,150,837  

Multiplied by the fair value per share of the Calyxt common stock (2)

   $ 31.50  
  

 

 

 

Estimated purchase price

   $ 634,751,334  
  

 

 

 

 

(1)

This Share number represents the aggregate number of Shares issued to Cibus Global members in the Merger and comprises: 15,508,202 shares of Class A Common Stock and 4,642,635 shares of Class B Common Stock. This Share number excludes 1,019,282 restricted shares of Class A Common Stock, which are subject to vesting conditions.

(2)

Reflects the assumed purchase price per share of Calyxt, Inc. common stock, which is the closing price of Calyxt, Inc.’s common stock on May 31, 2023, the closing date of the Merger.


3. Purchase Price Allocation

The Company has performed a preliminary valuation analysis of the fair market value of Cibus Global’s assets and liabilities. The following table summarizes the preliminary purchase price allocation as of the acquisition date (in thousands):

 

Cash and cash equivalents

   $ 13,997  

Accounts receivable

     1,413  

Due from related parties, net

     196  

Employee retention credit receivable

     2,062  

Note receivable

     1,000  

Prepaid expenses and other current assets

     1,182  

Property and equipment

     10,303  

Operating lease right-of-use-assets

     10,150  

Other assets

     471  

In-process research and development, intangible asset

     43,966  

Goodwill

     659,376  

Accounts payable

     (4,255

Accrued expenses

     (6,273

Due to related party

     (79

Deferred revenue

     (1,292

Notes payable, current portion

     (614

Operating lease liabilities, current portion

     (4,659

Financing lease liabilities, current portion

     (152

Other current liabilities

     (1,067

Notes payable, net of current portion

     (727

Operating lease liabilities, net of current portion

     (6,735

Financing lease liabilities, net of current portion

     (49

Royalty liability - related parties

     (81,944

Other non-current liabilities

     (1,519
  

 

 

 

Estimate of consideration expected to be transferred

   $ 634,751  
  

 

 

 

This preliminary purchase price allocation has been used to prepare pro forma adjustments in the pro forma balance sheet. The final purchase price allocation will be determined when the Combined Company has completed the detailed valuations and necessary calculations. The final allocation could differ materially from the preliminary allocation used in the pro forma adjustments. The final allocation may include material changes in allocations to the Royalty Liability, tax receivables liability, deferred tax liabilities and intangible assets such as trademark, developed technologies, in-process research and development technologies as well as goodwill and other changes to assets and liabilities.


4. Shares Issued to Cibus Unitholders upon Closing of the Mergers

At the closing of the Mergers, all outstanding Cibus Global equity converted into the right to receive Shares as consideration for the Mergers in the amounts as set forth in an allocation schedule provided for in the Merger Agreement and updated as of May 31, 2023, which resulted at the closing of the Mergers, in the Company issuing to holders of Cibus Global equity instruments and aggregate number of Shares representing approximately 95% of the aggregate number of outstanding Shares at closing. The allocation schedule is based on an exchange ratio of approximately 0.0634 determined as of January 13, 2023 based on stipulated values of Cibus Global and Calyxt, Inc. At closing of the Mergers, the Company issued an aggregate of 20,150,837 Shares to holders of Cibus Global equity instruments, determined as follows:

 

Cibus Global:

  

Cibus Global non-voting common units with threshold (1)

     45,797,340  

Cibus Global warrants (1)

     29,751,050  
  

 

 

 

Total pre-closing Cibus Global warrants and non-voting common units with threshold

     75,548,390  

Weighted average exchange ratio applicable to Cibus Global warrants and non-voting common units with threshold

  

Exchange ratio (rounded)

     0.0515  
  

 

 

 

Total Cibus, Inc. post-Mergers Shares for Cibus Global warrants and non-voting common units with threshold

     3,891,509  
  

 

 

 

Plus:

  

Cibus Global non-voting common units

     1,475,059  

Cibus Global preferred units

     254,936,576  
  

 

 

 

Total pre-closing Cibus Global preferred units and non-voting common units

     256,411,635  

Exchange ratio (rounded)

     0.0634  
  

 

 

 

Total Cibus, Inc. post-Mergers Shares for Cibus Preferred Units and non-voting common units

     16,259,328  
  

 

 

 

Total Cibus, Inc. post-Mergers Shares

     20,150,837  
  

 

 

 

 

(1)

Per the Merger Agreement, the outstanding non-voting restricted common units of Cibus Global, as well as outstanding warrants to purchase units of Cibus Global, converted based on the fair value of such units, as a percentage of the Calyxt Inc. common stock value, multiplied by the conversion ratio of approximately 0.0515. This resulted in a weighted average conversion ratio applicable to the units which varies from the conversion ratio applied to Cibus Global preferred units and pre-Mergers Cibus Global non-voting common units without an applied threshold value.

The exchange ratio has been adjusted to give retrospective effect to the Reverse Stock Splits.

5. Pro Forma Adjustments

The unaudited pro forma combined financial information includes pro forma adjustments that reflect transaction accounting adjustments, as well as other adjustments deemed to be directly related to the Mergers and the Reverse Stock Splits, irrespective of whether or not such adjustments are deemed to be recurring.


Based on the Company’s review of Cibus Global’s summary of significant accounting policies, the nature and amount of any adjustments to the historical financial statements of Cibus Global to conform to the Company’s accounting policies are not expected to be significant.

The unaudited pro forma combined financial information reflects the Reverse Stock Splits.

The pro forma adjustments, based on preliminary estimates that may change significantly as additional information is obtained, are as follows:

 

  (a)

To reflect preliminary estimated transaction costs of $3.8 million in connection with the Mergers, such as adviser, legal, and accounting expenses that are expected to be incurred by Calyxt, Inc.; an increase in selling, general and administrative expenses in the unaudited proforma combined statement of operations for the year ended December 31, 2022; a decrease of $1.2 million in selling general and administrative expense in the in the unaudited proforma combined statement of operations for the three months ended March 31, 2023 for the portion of costs expensed in the period; and a $2.6 million increase in accrued liabilities and accumulated deficit in the unaudited pro forma combined balance sheet as of March 31, 2023 for the portion of costs not yet incurred or accrued as of the balance sheet date.

 

  (b)

To reflect the change in Calyxt, Inc.’s common stock’s par value and additional paid-in capital upon the exchange of Cibus Global equity interests for Shares upon the closing of the Mergers.

 

     Common
Shares
 

Shares to Cibus Global holders (1)

     20,150,837  

Shares held by Calyxt Stockholders

     1,074,397  
  

 

 

 

Total shares

     21,225,234  
  

 

 

 

Par value per share

   $ 0.0001  
  

 

 

 

Aggregate par value of shares (in thousands)

     2  

Aggregate par value of Calyxt Common Stock (in thousands)

     (1
  

 

 

 

Par value adjustment (in thousands)

   $ 1  
  

 

 

 

 

(1)

This Share number represents the aggregate number of Shares issued to Cibus Global members in the Merger and comprises: 15,508,202 shares of Class A Common Stock and 4,642,635 shares of Class B Common Stock. This Share number excludes 1,019,282 restricted shares of Class A Common Stock, which are subject to vesting conditions.

 

  (c)

To reflect the elimination of Cibus Global’s historical accumulated deficit, accumulated other comprehensive loss, unit subscription receivable, and additional paid-in capital balances.


  (d)

The pro forma combined basic and diluted net loss per share of Class A Common Stock have been adjusted to reflect the pro forma net loss for the three months ended March 31, 2023 and the year ended December 31, 2022. In addition, the number of shares of Class A Common Stock used in calculating the pro forma combined basic and diluted net loss per share of Class A Common Stock has been adjusted to reflect the total number of shares of Class A Common Stock that are outstanding as of the closing of the Mergers, including all Series F preferred units issued prior to the closing of the Mergers. $59.6 million of gross proceeds related to the Series F preferred units, which was received subsequent to March 31, 2023, is not reflected in the pro forma adjustments in the balance sheet.

For the three months ended March 31, 2023 and year ended December 31, 2022, the pro forma weighted average shares of Class A Common Stock outstanding has been calculated as follows:

 

     Three Months Ended      Year Ended  
     March 31, 2023      December 31, 2022  

Historical Cibus Global weighted-average common units outstanding

     40,743,549        38,624,893  

Impact of Cibus Global convertible preferred units assuming conversion as of January 1, 2022

     222,194,079        222,194,079  

Impact of Cibus Global convertible preferred units converted to Class B Common Stock as of January 1, 2022

     (73,217,113      (73,217,113
  

 

 

    

 

 

 

Subtotal

     189,720,515        187,601,859  

Application of exchange ratio to historical Cibus Global convertible preferred units outstanding (rounded)

     0.0634        0.0634  
  

 

 

    

 

 

 

(a) Subtotal

     12,030,016        11,895,673  
  

 

 

    

 

 

 

Impact of accelerated vesting for Cibus Global non-voting common units with threshold, assuming conversion as of January 1, 2022

     3,766,988        3,766,988  

Application of weighted average exchange ratio for accelerated vesting of non-voting common units with threshold (rounded)

     0.0570        0.0570  
  

 

 

    

 

 

 

(b) Subtotal

     214,803        214,803  
  

 

 

    

 

 

 

Impact of Cibus Global warrants, assuming conversion as of January 1, 2022

     29,751,050        29,751,050  

Application of exchange ratio to historical Cibus Global warrants outstanding (rounded)

     0.0402        0.0402  
  

 

 

    

 

 

 

(c) Subtotal

     1,195,752        1,195,752  
  

 

 

    

 

 

 

Adjusted Cibus Global weighted-average common units outstanding (after giving effect to the Exchange Ratio)
(a + b + c)

     13,440,571        13,306,228  
  

 

 

    

 

 

 

Historical Calyxt, Inc. weighted-average shares of common stock outstanding

     988,139        919,951  

Impact on Calyxt, Inc. Common Stock of acclerated vesting of equity awards as of January 1, 2022

     97,413        28,209  
  

 

 

    

 

 

 

Total weighted average units outstanding

     14,526,123        14,254,388  
  

 

 

    

 

 

 

Less: Historical Cibus Global weighted-average units outstanding

     2,583,514        2,449,171  

Less: Historical Calyxt, Inc. weighted-average shares of common stock outstanding

     988,139        919,951  
  

 

 

    

 

 

 

Total weighted average units outstanding - pro forma adjustment

     10,954,470        10,885,266  
  

 

 

    

 

 

 

 

  (e)

To reflect $4.4 million in share-based compensation expense for Calyxt, Inc. as a result of the transaction, based on the fair value of awards for which vesting was accelerated based on the original grant terms, in connection with the Mergers.

 

  (f)

To reflect Calyxt, Inc.’s estimated compensation expense of $2.8 million related to severance payments resulting from pre-existing employment agreements that are payable in cash in connection with the Mergers but were not incurred as of December 31, 2022. These expenses are reflected as an increase to accrued expenses and accumulated deficit in the unaudited pro forma combined balance sheet. Calyxt, Inc.’s compensation costs of $2.8 million are reflected as selling, general and administrative expenses in the unaudited pro forma combined statement of operations for the year ended December 31, 2022.

 

  (g)

To reflect the impact of the redeemable noncontrolling interest created upon the election of historical holders of Cibus units to elect to receive “Up-C” units as consideration in connection with the Mergers, which is approximately 22% of the historical Cibus Global units.


  (h)

To reflect the impact of the preliminary purchase price allocation as described in Note 3, including the preliminary estimate of goodwill, the acquisition date fair value of land, buildings, and equipment, the royalty liability—related parties, and the deferred tax liability, and recognition of the intangible assets at the preliminary fair value, offset by the associated impact on amortization expense. The following table summarizes the intangible assets acquired (in thousands):

 

     Preliminary
Fair Value
     Estimated
Weighted-
Average
Useful Life
     Amortization
Expense for
Three Months
Ended March 31,
2023
     Amortization
Expense for
Year Ended
December 31,
2022
 

IPR&D (1)

   $ 20,371         $ —        $ —    

Developed technology

     9,995        20        125        500  

Trade name

     13,600        20        170        680  
  

 

 

       

 

 

    

 

 

 

Total Pro forma Adjustment

   $ 43,966         $ 295      $ 1,180  
  

 

 

       

 

 

    

 

 

 

 

(1)

In-process research and development (“IPR&D”) assets are initially recognized at fair value and are classified as indefinite-lived assets until the successful completion or abandonment of the associated research and development efforts. Accordingly, during the research and development period after the closing date of the Mergers, these assets will not be amortized. Such IPR&D projects will become amortizable when applicable products, which are currently in various stages of development, are complete.

 

  (i)

To reflect the elimination of the $1.0 million note receivable / short-term interim financing debt for amounts borrowed from Cibus Global by Calyxt, Inc. pursuant to the Merger Agreement, which was settled in connection with the closing of the Mergers.

 

  (j)

The total impact to redeemable noncontrolling interest and equity for the above adjustments is reflected in the table below. The redeemable noncontrolling interest has been classified within mezzanine equity due to the presence of conditions that would allow holders to cause redemption:

 

          Common Stock                                      
          Cibus Global     Calyxt, Inc.     Additional
Paid-in-Capital
    Unit Subscription
Receivable
    Accumulated
Deficit
    AOCI     Stockholders
Equity
    Non-Controlling
Interest
 

(amounts in thousands,

except share amounts)

        Units     Amount     Shares     Amount  

Purchase price allocation fair value

    (h     —         —         —         —         677,688       —         —         —         677,688       —    

Pre-combination stock-based compensation costs for Calyxt, Inc.

    (e     —         —         —         —         4,404       —         (4,404     —         —         —    

Elimination of historical Cibus Global APIC and accumulated deficit

    (c     —         —         —         —         (434,489     4,080       430,409       —         —         —    

Exchange of outstanding Cibus Global member units into Calyxt, Inc. common stock based on the assumed exchange ratio

    (b     (272,406,478     (334,241     20,150,837       1       334,240       —         —         —         —         —    

Severance payments to Calyxt, Inc. employees

    (f     —         —         —         —         —         —         (2,834     —         (2,834     —    

Transaction costs incurred by Calyxt Inc., associated with the Mergers

    (a     —         —         —         —         —         —         (2,600     —         (2,600     —    

Impact of redeemable noncontrolling interest

    (g     —         —         —         —         (138,235     —         —         —         (138,235     138,235  
   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Pro forma adjustment

      (272,406,478   $ (334,241     20,150,837     $ 1     $ 443,608     $ 4,080     $ 420,571     $ —       $ 534,019     $ 138,235